The contractor shall perform a phase i clinical study to evaluate infectivity, safety, and immunogenicity of a single intranasal dose of the recombinant live-attenuated RSV vaccine lid/DELTAM2-2/1030S…
Ended Awarded Last action
- Contract number
- 75N93020F00001
- Awardee
-
The Johns Hopkins University UEI FTMTDMBR29C7
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,109,347
Award facts
- Opportunity
-
- Operation of a Facility for the Study of Infectious Agents, Vaccines and Antivirals in Adult and Pediatric Human Subjects Solicitation · Posted Sep 12, 2018
- Contract value 100% obligated
- $4,109,347.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Baltimore, MD 21218, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $780,054 | |
| Change Order | $0 | |
| Original award | $3,329,293 |
About this award
This is a $4,109,347 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, to The Johns Hopkins University (JHU) to perform a Phase I clinical study evaluating the infectivity, safety, and immunogenicity of a recombinant live-attenuated respiratory syncytial virus (RSV) vaccine. The contract is part of NIAID's program to evaluate pediatric RSV vaccine candidates.
The contract has two key subcontracts - one with Vanderbilt University Medical Center (VUMC) and another with the University of Rochester. Both subcontractors will assist with carrying out the Phase I clinical study. There is no set-aside designation for this contract.
Description
The contractor shall perform a phase i clinical study to evaluate infectivity, safety, and immunogenicity of a single intranasal dose of the recombinant live-attenuated RSV vaccine lid/DELTAM2-2/1030S in RSV seronegative children and infants.
Quick answers
Who was awarded contract 75N93020F00001?
75N93020F00001 was awarded to The Johns Hopkins University by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 10, 2020.
How much is contract 75N93020F00001 worth?
The government has obligated $4,109,347 on 75N93020F00001.
Is contract 75N93020F00001 an order under another contract?
Yes. 75N93020F00001 is a delivery order under 75N93019D00031, an indefinite delivery contract.
Was contract 75N93020F00001 competed?
The extent of competition for 75N93020F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award